Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJSE:920433's PB Ratio is ranked worse than 70.99% of 917
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BJSE:920433: 3.40
During the past 12 months, Inner Mongolia Grand Pharmaceutical Co's average Book Value Per Share Growth Rate was -15.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Inner Mongolia Grand Pharmaceutical Co was 34.50% per year. The lowest was -7.10% per year. And the median was 10.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Inner Mongolia Grand Pharmaceutical Co PB Ratio Related Terms
Inner Mongolia Grand Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inner Mongolia Grand Pharmaceutical Co PB Ratio Chart
Inner Mongolia Grand Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Inner Mongolia Grand Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inner Mongolia Grand Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
Inner Mongolia Grand Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) has a PB Ratio of 3.40 as of Sep. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inner Mongolia Grand Pharmaceutical Co and its competitors. This is 38% above median its historical median of 2.47. Over the past decade, Inner Mongolia Grand Pharmaceutical Co's PB Ratio has ranged from 1.35 to 4.99. According to the industry distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #651 out of 917 companies in the Drug Manufacturers industry, placing it in the top 71%.
Is Inner Mongolia Grand Pharmaceutical Co's PB Ratio too high?
Inner Mongolia Grand Pharmaceutical Co's current PB Ratio of 3.40 is 38% above median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 1.35 to a high of 4.99. The Drug Manufacturers industry median PB Ratio is 1.98. Inner Mongolia Grand Pharmaceutical Co's value of 3.40 is 71.7% above this industry median. Based on the distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #651 out of 917 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Inner Mongolia Grand Pharmaceutical Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inner Mongolia Grand Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Inner Mongolia Grand Pharmaceutical Co ranks #651 out of 917 companies for PB Ratio. This places Inner Mongolia Grand Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.98. Inner Mongolia Grand Pharmaceutical Co's value of 3.40 is 71.7% above this benchmark. Historically, Inner Mongolia Grand Pharmaceutical Co's own PB Ratio has ranged from 1.35 to 4.99 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 1.98, Inner Mongolia Grand Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inner Mongolia Grand Pharmaceutical Co's current PB Ratio of 3.40 is 71.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Inner Mongolia Grand Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inner Mongolia Grand Pharmaceutical Co's current PB Ratio is 3.40, which is 38% above median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inner Mongolia Grand Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥3.89, compared to a current price of ¥4.94 — trading 27% above its estimated fair value. The current PB Ratio is 3.40, which is 38% above median its 10-year median of 2.47 and 71.7% above the Drug Manufacturers industry median of 1.98. Inner Mongolia Grand Pharmaceutical Co's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Inner Mongolia Grand Pharmaceutical Co (BJSE:920433), the current PB Ratio is 3.40 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inner Mongolia Grand Pharmaceutical Co (BJSE:920433) Overvalued in 2026?
Based on GuruFocus' analysis, Inner Mongolia Grand Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥4.94 is trading 27% above its estimated GF Value™ of ¥3.89.
GuruFocus considers Inner Mongolia Grand Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for BJSE:920433:
PB Ratio: 3.40 (38% above median its 10-year median of 2.47)
GF Value™: ¥3.89 vs. price of ¥4.94 (27% above fair value)
Industry Position: 71.7% above the Drug Manufacturers median (#651 of 917)
No single metric tells the full story. See the BJSE:920433 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inner Mongolia Grand Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating the development of Mongolian medicine resources. It engages in the research and development, production, and sales of specialty medicines and general health products. The company's main business is the research and development, production of Chinese patent medicines (including ethnic medicines) and chemical preparations, and sales.
70GF Score
Get the complete analysis for BJSE:920433
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920433 has been successfully added to your 
